The conceptual basis for molecular mimicry was first defined in the early 1980s when monoclonal antibodies against viruses were also shown to react with non-viral host protein; in this case, measles virus phosphoprotein cross-reacted with host cell cytokeratin, herpes simplex virus type 1 with host-cell vimentin and vaccinia virus with host-cell intermediate filaments. Following this discovery, others emerged, again at the clonal level, that T cell clones against proteins from a variety of infectious agents also reacted with host antigenic determinants. The clonal distinction was imperative for the initial definition of mimicry. At least 30 years prior to our initial description of molecular mimicry involving cross-reactions between numerous

Malaria is still a major global health problem, killing more than 1 million people every year. Almost all of these deaths are caused by Plasmodium falciparum, one of the four species of malaria parasites infecting humans. This high burden of mortality falls heavily on Sub-Saharan Africa, where over 90% of these deaths are thought to occur, and 5% of children die before the age of 5 years. The death toll from malaria is still growing, with malaria-specific mortality in young African children estimated to have doubled during the last twenty years. This increase has been associated with drug resistance of the parasite, spread of insecticide resistant mosquitoes, poverty, social and political upheaval, and lack of effective vaccines. This collection

Continuous genetic variation and selection of virus subpopulations in the course of RNA virus replications are intimately related to viral disease mechanisms. The central topics of this volume are the origins of the quasispecies concept, and the implications of quasispecies dynamics for viral populations

From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here

برای دانلود به ادامه مطلب بروید